Clin­i­cal tri­al starts slowed to be­low pre-pan­dem­ic lev­els last year, IQVIA analy­sis finds

Bio­phar­ma R&D spend­ing re­bound­ed in 2023, up $11 bil­lion from 2022 fol­low­ing a steep post-pan­dem­ic de­cline. But the num­ber of new clin­i­cal tri­al starts slowed to lev­els from be­fore the Covid-19 pan­dem­ic, the da­ta and ser­vices firm IQVIA said in a new re­port.

There are few­er pan­dem­ic-re­lat­ed tri­als, the analy­sis found, but al­so few­er of oth­er types of tri­als be­ing start­ed at both small and large bio­phar­ma com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER